siRNA Therapeutics
Total Trials
12
As Lead Sponsor
As Collaborator
0
Total Enrollment
1,710
NCT06082596
Study of BEBT-908 in Subjects With Advanced Hematological Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Mar 2, 2016
Completion: Mar 8, 2019
NCT06047184
Phase I Study of BEBT-209 in Women With Advanced Breast Cancer
Start: Jul 15, 2019
Completion: Nov 20, 2023
NCT06074107
Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
Phase: Phase 2
Start: Jun 12, 2020
Completion: Dec 25, 2023
NCT06706713
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Start: Apr 15, 2022
Completion: Jun 30, 2026
NCT06998108
Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy
Phase: Phase 3
Start: Jun 9, 2022
NCT05391880
Study of Orally Administered BEBT-503 in Healthy Subjects
Start: Aug 26, 2022
Completion: Jul 5, 2023
NCT06685796
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
Start: Apr 12, 2023
Completion: Dec 31, 2026
NCT06117371
Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
Start: Sep 4, 2023
Completion: Jun 30, 2025
NCT06164327
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start: Dec 1, 2023
Completion: Nov 5, 2025
NCT06514027
Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations
Start: Jul 31, 2024
Completion: Nov 30, 2027
NCT06792253
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Start: Jan 6, 2025
Completion: Jun 30, 2029
NCT07012109
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
Start: Jun 5, 2025
Completion: Jul 31, 2028
Loading map...